Rx Medicare

Medicare News

Flower

SciClone And Sigma-Tau Announce Positive Preliminary Results In Clinical Study Examining ZADAXIN’S Ability To Enhance Response To H1N1 Vaccine

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) and its partner Sigma-Tau S.p.A. have received initial topline results in a clinical study evaluating the potential of ZADAXIN? (thymalfasin) to enhance immune response to the MF59 adjuvanted H1N1 influenza monovalent vaccine, Focetria? from Novartis…

Read More…

  • Share/Bookmark

Related Posts

Tags: , , , , , , , , , , , , , , ,

Comments are closed.